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Abstract
Nitric oxide is implicated in the pathogenesis of various neuropathologies characterized by oxidative stress. Although nitric oxide has
been reported to be involved in the exacerbation of oxidative stress observed in several neuropathologies, existent data fail to provide a
holistic description of how nitrergic pathobiology elicits neuronal injury. Here we provide a comprehensive description of mechanisms
contributing to nitric oxide induced neuronal injury by global transcriptomic profiling. Microarray analyses were undertaken on RNA
from murine primary cortical neurons treated with the nitric oxide generator DETA-NONOate (NOC-18, 0.5 mM) for 8–24 hrs. Biological
pathway analysis focused upon 3672 gene probes which demonstrated at least a 1.5-fold expression in a minimum of one out of three
time-points and passed statistical analysis (one-way ANOVA, P  0.05). Numerous enriched processes potentially determining nitric oxide
mediated neuronal injury were identified from the transcriptomic profile: cell death, developmental growth and survival, cell cycle, cal-
cium ion homeostasis, endoplasmic reticulum stress, oxidative stress, mitochondrial homeostasis, ubiquitin-mediated proteolysis, and
GSH and nitric oxide metabolism. Our detailed time-course study of nitric oxide induced neuronal injury allowed us to provide the first
time a holistic description of the temporal sequence of cellular events contributing to nitrergic injury. These data form a foundation for
the development of screening platforms and define targets for intervention in nitric oxide neuropathologies where nitric oxide mediated
injury is causative.
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Introduction
Nitric oxide, endogenously synthesized in the mammalian system
by the nitric oxide synthases (NOS), continues to receive wide-
spread attention for its multifunctional roles in both physiological
and patho-physiological conditions. Under physiological condi-
tions, nitric oxide exerts pleiotrophic effects in different tissues.
For instances, within the vascular-endothelial system, nitric oxide
functions as an effective vaso-relaxant [1]. However, when present
in the central and peripheral nervous systems, nitric oxide
functions as a neurotransmitter [2]. On the other hand, nitric oxide
is an antitumoral and antimicrobial defense agent produced 
by immune and glial cells in the context of mammalian host
immunity [3].
With a half-life of only 3–5 sec in vivo, nitric oxide can readily
enter a cell or move between cells many times within this time
span [4] and react with the heme group of guanylate cyclase (GC), 
triggering a conformational change in GC and the catalysis of
guanosine-5-triphosphate (GTP) to cyclic guanosine 3,5-
monophosphate (cGMP) [4] and protein phosphorylation. GC acti-
vation is believed to be the main nitrergic signal transduction path-
way. cGMP acts as a second messenger that activates protein
kinase G 1 and 2, with the former involved in intracellular Ca2
control and the latter regulating anionic influx, for example chlo-
ride [5, 6]. This transduction pathway can affect a broad range of
proteins directly, for example phosphodiesterases of cyclic
nucleotides and indirectly, for example protein kinase A, thus
increasing the level of adenosine 3,5-monophosphate (cAMP)
with activation of proteins involved in the cAMP downstream 
pathway [7, 8].
Nitric oxide is capable of affecting other cellular signalling
pathways independent of GC activation. As nitric oxide is thermo-
dynamically unstable, it is able to undergo various chemical reac-
tions with gaseous molecules, anions and reactive oxygen species
(ROS) to form nitrites, nitrates and peroxynitrites (ONOO). Nitric
oxide reacts quickly with the superoxide anion (O2•) to form 
peroxynitrite (ONOO) to avoid its elimination by the antioxidant
systems. ONOO has an action radius of 100 m and even
shorter of half-life of 1–2 sec, tending to generate multiple toxic
products in its degradation [9]. During the process of these 
chemical reactions, intermediate products such as (ROS) and
other free radicals are produced. These nitrergic intermediate and
end-products can induce modifications of lipids, proteins and DNA
through oxidation [10], nitration [11] or nitrosylation [12].
The involvement of diverse functional nitric oxide in the nervous
system continues to attract researchers’ attention as its implication
in various neurodegenerative disorders linked to oxidative stress,
including ischaemia [13], amyotrophic lateral sclerosis [14],
Alzheimer’s disease (AD) [15] and Parkinson’s disease (PD) [16].
The bi-phasic role of nitric oxide either as a physiological neuro-
modulator or a neurotoxic factor is dependent on the level of 
intracellular nitric oxide. Nitric oxide induced cytotoxicity is signif-
icantly elevated in pathological conditions implicating the genera-
tion of ROS and ONOO as a key mechanism in brain injury where
they are both likely to mediate programmed cell death (PCD) [17,
18]. Moreover, iNOS induction by diverse stimuli such as endotox-
ins or cytokines and during excitotoxicity caused by constitutive
activation of glutamate receptors can result in overproduction of
nitric oxide because of increased nNOS activity [19]. Chronic
Aß1–40 intracerebroventricular infusion in an AD model has been
demonstrated to induce ONOO formation resulting in nitration of
tyrosyl residues of proteins [20]. In ischaemia/reperfusion and
stroke models, the higher nitric oxide level is accounted for by
increased synthesis activity of iNOS and the constitutive isoforms
of NOS triggered by elevated Ca2 level [21]. However, the role of
nitric oxide in ischaemia remains controversial. Inhibition of nitric
oxide production in iNOS and nNOS knockout mice or by non-
selective pharmacological inhibitor has demonstrated neuropro-
tective effects in models of cerebral ischaemia [22] and traumatic
brain injury [23], respectively. On the contrary, [24] demonstrated
that pre-treatment with NOS inhibitor aggravated neuronal death
whereas post-treatment showed no neuronal rescue effect on
cerebral ischaemia injury. In PD, inhibition of parkin [25] and glu-
tathione reductase [26] activities by ONOO-induced protein
modification increased susceptibility to neuronal death as a result
of lower cellular antioxidant defense.
As nitric oxide has widespread implications in the pathogene-
sis of numerous neurodegenerative diseases because of its toxic
and undesirable interaction with ROS, an understanding of the
mechanisms of nitric oxide mediated neuronal injury provides a
screening platform for identification of potential universal biologi-
cal targets involved in neuronal death. Our current study of the
neuronal transcriptome revealed a stunning list of 3672 probe sets
exhibiting transcriptional regulation of at least 1.5-fold change
in a minimum of one out of three time-points (8, 15 and 24 hrs)
in nitric oxide mediated neuronal injury. Biological functional
annotation of these genes revealed that multiple enriched biologi-
cal processes were significantly regulated. Although some of
these over-represented pathways have been documented to a
degree, many are novel providing unique insights into nitric oxide
related neuronal injury, enabling us to define the temporal profile
of recruitment of death signalling.
Materials and methods
Materials
Neurobasal™ (NB) medium, B-27 and GlutaMAX supplements were from
Invitrogen/GIBCO™ (Carlsband, CA, USA). Cell culture plates were from
NUNC (Naperville, IL, USA). NOC-18 (DETA-NONOate, (Z)-1-[2-(2-
Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate from
Alexis Biochemical (San Diego, CA, USA). The primary antibodies used in
Western blot analysis were as follows: active caspase-3 antibody from BD
Biosciences PharMingen (San Diego, CA, USA); -fodrin antibody from
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 16, No 1, 2012
43
Chemicon (Temecula, CA, USA) and 	-tubulin antibody from Cytoskeleton
(St. Denver, CO, USA). All other nutrients, salts and antibiotics used in the
culture media or assay buffers were from Sigma (Singapore).
Cell culture preparation for murine 
primary cortical neurons
The primary cultures were prepared by using neocortical neurons (gesta-
tional days 15 or 16) obtained from foetal cortices of Swiss albino mice fol-
lowing previous described procedures with modifications [27].
Microdissected cortices were subjected to trypsin digestion and mechani-
cal trituration. Cells were collected by centrifugation and resuspended in
NB medium containing 2.5% B-27 supplement, 1% penicillin, 1% strepto-
mycin, 0.25% GlutaMAX-1 supplement and 10% dialysed foetal calf
serum. Twenty-four well plates previously coated with poly-D-lysine (100
g/ml) were seeded with cells at a density of 2 
 105 cells/cm2 and used
for subsequent experiments. The cultures were maintained at 37C
overnight in a humidified 5% CO2 and 95% air incubator and the culture
media changed to a serum-free NB medium containing all previously men-
tioned constituents. Immunocytochemical staining for microtubule-associ-
ated protein-2 and glia fibrillary acidic protein revealed more than 95% of
the cells in day 5 in vitro cultures were neurons with minimal contamina-
tion by glia [27]. All experiments involving animals were approved by the
National University of Singapore (Protocol no. 727/05) and were in accor-
dance with the Ethical principles and guidelines for scientific experiments
on animals’ of the Swiss Academy of Medical Sciences.
Drug preparation and treatment
Nitric oxide donor, NOC-18 was prepared as 100 mM aqueous stock 
solution containing 0.01 M sodium hydroxide (NaOH) and stored at –20C.
On day 7 in vitro, the cultured neurons were treated with respective drug
in NB medium.
Hoechst stain
Cells were fixed with 4% paraformaldehyde in phosphate buffered saline.
Fixed cells were then incubated with Hoechst 33342 at the final concentra-
tion of 2 g/ml. Stained nuclei were observed and analysed under a fluo-
rescence microscope (Leica DM IRB).
Qualitative and quantitative analysis 
of cell viability
The 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was employed as index of cell survival [27]. MTT was dissolved at a
stock concentration of 5 mg/ml in RPMI-1640 medium (GIBCO). Thirty
microlitres of MTT solution was added to each well of the 24-well plate
containing 300 l culture medium. After incubation at 37C for 20 min, 
the culture medium was removed by aspiration. The formazan formed in
the wells was dissolved by an aliquot of 200 l DMSO and the absorbance
of the solution was read using a TECAN plate reader at a wavelength of 
570 nm. Results from MTT assay are presented as mean  S.E.M. from
three independent experiments.
Western blotting
Cells were lysed with RIPA buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA,
150 mM NaCl, 1% Nonidet-P40, 0.5% deoxycholate, 0.1% SDS, protease
inhibitor cocktail tablet) and spun down at 16,000 
 g for 10 min to obtain
the supernatants whose concentrations were quantitated using Biorad RC-
DC assay. Ten micrograms of proteins from individual supernatant samples
containing 1
 SDS (with 20% freshly added 	-mercaptoethanol) were
heated to 100C for 5 min, cooled down to room temperature and subse-
quently centrifuged for 2 min at 16,000 
 g. Equal amount of protein was
loaded and subjected to SDS-PAGE (12% gel) and immunoblotted using
commercially available antibodies. Antitubulin (1:1000; Cytoskeleton Inc.,
St. Denver, CO, USA) monoclonal antibody was used for internal control
purpose. Antibody-reactive bands were detected using chemiluminescence
(Pierce Biotechnology Inc., Rockford, IL, USA) and exposure to x-ray film
(Eastman Kodak Company, Rochester, New York, USA).
Total RNA extraction and isolation
RNA from samples was extracted using RNeasy Mini Kit (Qiagen Cat. No.
74104) according to the manufacturer’s instructions. All pipette tips 
used were RNase-free and with filters. The following procedures were
suited for 1 
 106 cultured cells per sample. 1.5 l of the RNA sample was
aliquoted for spectrophotometric quantification using Nanodrop ND-1000
Version 3.2.1 and 1 l for RNA quality analysis using E-gene HDA-GT12
genetic analyser.
Affymetrix microarray using Affymetrix®
GeneChip Mouse Genome 430 2.0 array
Microarray analysis was carried out using 14 GeneChip Mouse Genome
430 2.0 array (Affymetrix, Santa Clara, CA, USA), which contain 45,000
probe sets and can analyse the expression level of over 39,000 transcripts
and variants from over 34,000 well-characterized mouse genes. The
assignment of the arrays (GeneChip) was as follows: vehicle-treated 
control (n  5); NOC-18-treatment for 8, 15 and 24 hrs NOC-18 treatment
(n  3 for each time-point).
According to technical manual form Affymetrix, 7 g of extracted total
RNA was used for cDNA synthesis. Double-stranded cDNA was synthe-
sized using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA,
USA) with a T7-dT24 primer. After cleanup, Biotin-labelled cRNA was
synthesized by in vitro transcription (Enzo Diagnostic, Inc., NY, USA) and
fragmented subsequently. Fifteen micrograms of fragmented cRNA
produced above was hybridized to the arrays for 16 hrs at 45C. The
hybridized arrays were washed, stained, and scanned according to the
manufacturer’s instructions. The data from each array were collected and
initially analysed using Affymetrix Microarray Suite 5.0 software. For com-
parison of multiple arrays, the signal intensity of each array was scaled to
500. The regulated genes were filtered on fold change 1.5-fold against
controls in at least one of three time-points. One-way ANOVA (P  0.05)
approach was used to find differentially expressed genes using
GeneSpring™ GX 7.3 software (Agilent Technologies, CA, USA). Functional
information about each gene product was obtained from web-based data-
base NetAffx (3 IVT Expression, Affymetrix), web-based applications
DAVID 2008 (http://david.abcc.ncifcrf.gov/) and from direct searches of
the primary literature (PubMed: http://www.ncbi.nlm.nih.gov/pubmed/).
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
44
Microarray bioinformatics analysis
The absolute data (signal intensity, detection call and detection P value)
were exported into GeneSpring(tm) GX 7.3 (Agilent Technologies, 
San Diego, CA, USA) software for analysis by parametric test based on
crossgene error model. One-way ANOVA approach was used to identify
differentially expressed genes. Array data were globally normalized using
GeneSpring software. After per chip normalizations and per gene normal-
ization, genes were filtered on fold change 1.5-fold against controls 
in at least one of three conditions. Finally, one-way ANOVA approach 
(P  0.05) and Benjamini-Hochberg FDR Correction were used to find
differentially expressed genes. Genes which were differentially expressed
are annotated using Database for Annotation, Visualization, and Integrated
Discovery (DAVID) V6.7 (http://david.abcc.ncifcrf.gov/) and PubMed
(http://www. ncbi.nlm.nih.gov/pubmed/) search. All microarray data
reported here is described in accordance with MIAME guidelines and 
has been deposited in NCBIs Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO 
Series accession number GSE22087 for nitric oxide global transcriptomic
profile.
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 1 (A) Cell viability assay revealed a
dose-dependent increase in neuronal death
of NOC-18-treated primary cortical neurons.
Day 7 murine primary cortical neurons were
treated with NOC-18, A nitric oxide donor, at
various concentrations. MTT assay was
conducted 24 hrs later. Data are representa-
tive of three independent experiments per-
formed in replicates (*P  0.05 as com-
pared with the control). (B) Round shrunken
apoptotic bodies with chromatin condensa-
tion were observed in nitric oxide induced
neuronal injury. Hoffman imaging of control
(i) and 0.5 mM NOC-18-treated (ii) primary
cortical neurons was performed after 24 hrs
post-treatment (Top). Hoechst nuclei stain
was subsequently carried out to reveal
extent of chromatin condensation in control
(iii) and nitric oxide treated (iv) neurons
(Bottom). Each scale bar represents 10 m.
Data are representative of three independent
experiments.
J. Cell. Mol. Med. Vol 16, No 1, 2012
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Real-time PCR
Reverse transcription was carried out according to steps specified by man-
ufacturer (Applied Biosystems Taqman reverse transcription reagents).
Each cDNA sample was duplicated with two No Template Control (NTC) for
each probe used. Twenty microlitres of the Taqman master mix was pipet-
ted to the bottom of each well of the optical 96-well fast reaction plate. Five
microlitres of cDNA or water (NTC) was added to the designated reaction
well. The plate was then read by the 7000 Fast Real-Time PCR System with
conditions according to the manufacturer’s protocol.
Statistical analysis
Values are mean  S.E.M. of at least three independent experiments. Data
were analysed using Tukey test with one-way ANOVA to assess significant
differences in multiple comparisons. Values of P  0.05 were considered
as statistically significant and presented as mean  S.E.
Results
Nitric oxide induced apoptotic cell death 
in cultured primary neurons
High doses of nitric oxide, frequently observed in the pathogene-
sis of neurodegenerative disease, cause neuronal death. In this
study, we adopt a neuronal model of cultured day 7 murine pri-
mary cortical neurons. Cell viability assay demonstrated a concen-
tration-dependent decrease in cell viability after 24 hrs treatment
with NOC-18 (a nitric oxide donor; Fig. 1A). As determined from
Figure 1A, the IC50 for nitric oxide was 0.5 mM (51.2  4.0% cell
viability). Morphological analysis of 0.5 mM NOC-18-treated neu-
rons by Hoffman modulation contrast imaging demonstrated cell
shrinkage into round apoptotic cell bodies with absence of neuritic
outgrowths and [Fig. 1B(ii)] when compared to the healthy control
neurons [Fig. 1B(i)]. There was an absence of rapid swelling indi-
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Fig. 2 (A) Immunoblotting against pro- and
active caspase-3 revealed caspase-3 activa-
tion at 15 hrs after 0.5 mM NOC-18 treat-
ment. Pro-caspase-3, a 32 kD pro-enzyme 
is cleaved into two functional subunits of 17
and 11 kD, respectively, to form the active
caspase-3 complex. (B) Immunoblotting
against -fodrin demonstrated simultane-
ous caspase-3 and calpains activation at 
15 hrs after 0.5 mM NOC-18 treatment. 
-Fodrin, a common substrate to both 
caspase-3 and calpains, is cleaved to 120 kD
and 145/150 kD protein fragments upon
caspase-3 and calpains activation, respec-
tively. Initial expression of the 120 and
145/150 kD occurred at 15 hrs post-NOC-18
treatment on murine primary cortical neurons.
Cultured neurons were treated with 0.5 mM
NOC-18 and samples harvested with RIPA
buffer from 4 to 24 hrs post-treatment. Ten
micrograms of supernatent proteins from
individual treatment was loaded in each 
lane and subjected to SDS-PAGE and
immunoblotting analysis. Staurosporine
(STA), a broad-spectrum kinase inhibitor, is
well known for its role in induction of mito-
chondrial-dependent caspase-3-mediated
neuronal death and is in this case used as a
positive control for neuronal treatment at
0.5 M. Each immunoblot is representative
of three independent analyses.
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cating that accidental necrosis was not involved [18]. In addition,
Hoescht stain illustrated the presence of chromatin condensation
in these round cell bodies [Fig. 1B(iv)] as opposed to that of con-
trol cells [Fig. 1B(iii)], further confirming induction of neuronal
death predominantly by apoptotic-like injury by 0.5 mM of NOC-
18. In this study, 0.5 mM of NOC-18 was chosen for subsequent
time-course experiments.
To understand the nature of nitric oxide induced neuronal
injury, immunoblot analysis against inactive pro-caspase-3 (32 kD)
and active caspase-3 (made up of a 12 and 17 kD subunits) 
was conducted. Figure 2A demonstrated a time-dependent
increase in caspase-3 activation, with prominent overexpression
of the active 17 kD subunit observed after 15 hrs post-treatment.
Caspase-3 activation was further confirmed by the presence of the
120 kD truncated -fodrin fragment from 15 hrs post-treatment
(Fig. 2B). Expression of the 145/150 kD -fodrin protein fragment
also suggested the presence of calcium-activated calpains activa-
tion in nitric oxide induced neuronal injury (Fig. 2B). These data
are suggestive of PCD, which is slow in onset and involves the
recruitment of multiple proteases [18].
Gene expression in nitric oxide induced neuronal
apoptosis
Affymetrix GeneChip Mouse Genome 430 V2.0 arrays were used
to perform the microarray experiment on day 7 murine primary
cortical neurons treated with 0.5 mM of NOC-18 over a time-
course of 8, 15 and 24 hrs. All differentially expressed genes in
this study were selected based on criteria of a minimum of 1.5-
fold change in at least one of three time-points and subjected to
statistical testing by one-way ANOVA, P  0.05 and Benjamini-
Hochberg False Discovery Rate (FDR) Correction using
GeneSpring v7.3 software. FDR, a commonly adopted statistical
analysis, controls the proportion of the most relevant errors
among those tests whose null hypothesis were rejected.
Out of a total of 45,000 probe sets representing over 34,000
well-characterized mouse genes, 3,672 microarray chip-annotated
probe sets were profiled after 0.5 mM NOC-18 treatment (Fig. 3A).
As demonstrated in Figure 3A, the number of down-regulated
genes at individual time-points in NOC-18 treatment substantially
overwhelmed the up-regulated genes. Across the three time-
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Fig. 3 Time-course profiling revealed a 
significant increase in number of up/down-
regulated genes with transcriptional expres-
sion twofold change from 8 to 24 hrs
timeframe. Only genes with transcriptional
fold-change of at least 1.5 in at least one
out of three time-points and had passed
stringent statistical analysis (one-way ANOVA,
P  0.05) were included into nitric oxide
global gene profile (a total of 3672 gene
probes). Genes were then segregated into
fold-change categories at respective time-
points.
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points, close to 30% of total gene probes demonstrated transcrip-
tional up-regulation above the basal level of 1.0-fold. Within these
up-regulated gene probes, the number of genes with fold-change
difference above 1.5 significantly increases from 49% (8 hrs) to
96% (24 hrs). This tremendous increase was attributed to the
expansion of the 2-fold change category from the initial 22% (8
hrs) to an escalating 58% (15 hrs), and continued on a slow
steady increase to 73% (24 hrs). A similar trend was also
observed for the down-regulated gene probes (Fig. 3). As such, it
can be inferred that the most significant transcriptional regulation
occurred between 8 and 15 hrs.
The global gene profile list representative of NOC-18-mediated
neuronal injury (3672 microarray chip-annotated probes sets) was
then subjected to functional-gene ontology classification by
DAVID 6.7 analysis [28, 29]. DAVID interpretation recognized
3484 biologically and functionally reported genes from various
biological databases for nitric oxide treatment (as shown in Fig. 4).
To derive inferences pertaining to the temporal recruitment 
of cellular pathways and functional processes were altered, we
performed a more structured over-representation analyses on the
identified genes. The 3484 differentially expressed annotated genes
were then classified into time-point-specific up/down-regulated
categories based on (1) their fold-change above/below 1.5 at the
specific time-point; and (2) if fold-change at the time-point is
between –1.5 and 1.5, the inter-time-point up/down regulatory
trend. This is to facilitate the identification of the temporal recruit-
ment and/or activation/inhibition of biological pathways during
nitric oxide mediated neuronal injury. To assess if a biological
process was statistically significantly enriched, DAVID in-built
Expression Analysis Systematic Explorer (EASE) program was
employed. It categorizes genes to functional categories within the
gene ontology hierarchical database and denotes which categories
in the biological process ontology are statistically over-represented
by identified genes. A P value  0.05 for a functional category
denotes significant overrepresentation, and 0.05  P values 
0.15 were considered borderline significant.
Despite the vast, useful information that DAVID has interpreted
from the global gene profile, its structure is inadequate in provid-
ing additional associations (e.g. cell type and pathway targets). To
complicate matter, many annotated genes on the microarray chip
have not yet been fully associated with categories in the appropri-
ate gene ontology hierarchies. This would explain the discrepancy
in the number of annotated probe sets between the microarray
chip (3672) and the DAVID (3484) defined groups. Consequently,
we further substantiate the pathway/process analyses with in-
depth literature review to identify and include additional clusters of
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Flowchart of microarray analyses and profiling of neuronal death-related differentially expressed genes in nitric oxide mediated neuronal injury.
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Table 1 Selected differentially expressed gene profile of neuronal death-related families in cultured day 7 mouse primary cortical neurons treated
with 0.5 mM NOC-18
GenBank Gene title Symbol 8 hrs 15 hrs 24 hrs
Cell death
60, P  4.45
 69, P  0.41
 49, P  5.404
 65, P  0.54
48, P  4.104
 65, P  0.52
NM_010019 Death-associated protein kinase 2 Dapk2 5.00  0.47 5.05  0.56 2.02  1.05
NM_020581 Angiopoietin-like 4 Angptl4 1.28  0.41 6.28  1.45 2.63  0.57
NM_133810 Serine/threonine kinase 17b (apoptosis-inducing) Stk17b 1.84  0.34 3.28  0.71 1.97  0.73
NM_054056 PRKC, apoptosis, WT1, regulator Pawr 1.61  0.34 3.22  0.66 2.32  0.55
NM_013929 SIVA1, apoptosis-inducing factor Siva1 –1.12 0.35 1.95  0.48 2.27  0.55
NM_009754 BCL2-like 11 (apoptosis facilitator) Bcl2l11 3.04  0.95 4.90  0.78 7.28  1.39
NM_013749 Tumour necrosis factor receptor superfamily, member 12a Tnfrsf12a 2.86  0.91 10.82 0.93 17.99  0.56
NM_146057 Death-associated protein Dap –1.22 0.32 2.09  0.48 2.28  0.54
NM_019740 Forkhead box O3 Foxo3 1.10  0.31 1.65  0.48 1.82  0.54
NM_019980 LPS-induced TN factor Litaf 1.23  0.32 1.95  0.48 1.96  0.57
NM_009068 Receptor (TNFRSF)-interacting serine-threonine kinase 1 Ripk1 1.18  0.37 1.50  0.59 1.70  0.56
Cell survival, growth and development
 27, P  0.048
 47, P  0.092
 49, P  0.13
 65, P  0.10
 48, P  0.20
 65, P  0.09
NM_011632 Tnf receptor-associated factor 3 Traf3 1.55  0.42 4.91  0.82 4.45  0.59
NM_011633 Tnf receptor-associated factor 5 Traf5 1.58  0.56 1.12  0.58 1.87  0.63
NM_007566 Baculoviral IAP repeat-containing 6 Birc6 1.01  0.66 1.59  0.66 1.74  0.69
NM_007540 Brain derived neurotrophic factor Bdnf 3.51  0.32 2.50  0.49 2.05  0.56
NM_010014 Disabled homologue 1 (Drosophila) Dab1 1.74  0.31 2.58  0.48 3.84  0.54
NM_007912 Epidermal growth factor receptor Egfr 2.57  0.32 3.39  0.65 1.17  0.54
NM_010207 Fibroblast growth factor receptor 2 Fgfr2 2.11  0.31 1.78  0.48 1.40  0.54
NM_184052 Insulin-like growth factor 1 Igf1 2.57  0.43 3.98  0.54 4.69  0.59
NM_010788 Methyl CpG binding protein 2 Mecp2 2.89  0.45 3.94  1.53 4.97  0.60
NM_013613 Nuclear receptor subfamily 4, group A, member 2 Nr4a2 4.40  0.31 4.04  0.75 4.67  0.54
NM_153529 Neuritin 1 Nrn1 1.72  0.31 1.89  0.49 2.05  0.54
NM_013625 Platelet-activating factor acetylhydrolase, isoform 1b, 	1 subunit Pafah1b1 1.32  0.31 1.77  0.48 2.74  0.54
NM_009367 Transforming growth factor-	2 Tgfb2 2.53  0.44 2.15  0.55 1.07  0.63
NM_009715 Activating transcription factor 2 Atf2 1.45  0.31 1.28  0.49 2.25  0.54
NM_139294 Braf transforming gene Braf 1.33  0.33 1.46  0.49 2.05  0.56
NM_007700 Conserved helix-loop-helix ubiquitous kinase Chuk 1.09  0.32 2.12  0.48 1.84  0.55
NM_021461 MAP kinase-interacting serine/threonine kinase 1 Mknk1 2.07  1.32 3.95  1.08 2.70  0.88
NM_013672 Trans-acting transcription factor 1 Sp1 1.11  0.31 1.70  0.49 1.75  0.54
NM_010234 FBJ osteosarcoma oncogene Fos 31.00 1.08 21.65  5.39 16.78 0.81
NM_008036 FBJ osteosarcoma oncogene B Fosb 29.07 1.36 13.76  4.48 7.25  1.53
NM_010591 Jun oncogene Jun 8.63  0.34 6.99  1.18 7.48  0.54
NM_008416 Jun-B oncogene Junb 7.48  0.76 6.07  0.69 3.86  0.54
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Table 1 Continued
GenBank Gene title Symbol 8 hrs 15 hrs 24 hrs
Mitotic cell cycle regulation
 35, P  1.15
 51, P  6.04
 26, P  4.14
 54, P  5.25
 19, P  0.14
 54, P  4.55
NM_023813 Calcium/calmodulin-dependent protein kinase II, delta Camk2d 2.38  0.35 6.23  0.49 4.76  0.69
NM_009828 Cyclin A2 Ccna2 1.28  0.31 1.73  0.48 –1.70  0.54
NM_172301 Cyclin B1 Ccnb1 1.34  0.33 1.82  0.49 –3.18 0.54
NM_009831 Cyclin G1 Ccng1 1.13  0.44 2.55  0.48 4.27  1.07
NM_019937 Cyclin L1 Ccnl1 1.19  0.31 1.94  0.48 1.61  0.54
NM_023223 Cell division cycle 20 homologue (S. cerevisiae) Cdc20 1.05  0.31 1.66  0.57 –1.76  0.55
NM_145436 Cell division cycle 27 homologue (S. cerevisiae) Cdc27 1.32  0.32 1.47  0.48 2.12  0.54
NM_027118
Cell division cycle 2-like 5 (cholinesterase-related cell 
division controller)
Cdc2l5 2.31  0.44 3.77  0.49 4.34  0.57
NM_009874
Cyclin-dependent kinase 7 (homologue of Xenopus 
MO15 cdk-activating kinase)
Cdk7 1.12  0.31 1.52  0.48 1.87  0.54
NM_026014 Chromatin licensing and DNA replication factor 1 Cdt1 1.33  0.31 1.83  0.48 2.81  0.56
NM_007862 Discs, large homologue 1 (Drosophila) Dlg1 1.06  0.32 1.39  0.48 1.85  0.54
NM_013642 Dual specificity phosphatase 1 Dusp1 2.13  0.31 2.30  0.48 1.91  0.54
NM_007893 E4F transcription factor 1 E4f1 1.20  0.32 1.65  0.48 2.05  0.54
NM_011808 E26 avian leukemia oncogene 1, 5 domain Ets1 1.86  0.49 2.67  0.57 1.95  0.62
NM_183186 Forkhead box N3 Foxn3 1.45  0.32 1.62  0.48 –1.00  0.55
NM_007836 Growth arrest and DNA-damage-inducible 45 Gadd45a 1.31  0.85 5.09  0.87 9.65  0.80
NM_008655 Growth arrest and DNA-damage-inducible 45	 Gadd45b 3.68  0.35 7.48  0.99 5.72  1.35
NM_011817 Growth arrest and DNA-damage-inducible 45 Gadd45g 5.46  0.31 9.09  1.30 8.80  0.54
NM_007569 B-cell translocation gene 1, antiproliferative Btg1 1.44  0.31 1.95  0.48 1.75  0.55
NM_007570 B-cell translocation gene 2, antiproliferative Btg2 4.20  0.37 5.75  1.22 6.65  0.96
NM_009770 B-cell translocation gene 3 Btg3 2.96  0.31 5.53  0.84 5.14  0.54
NM_007669 Cyclin-dependent kinase inhibitor 1A (p21) Cdkn1a –1.23  0.31 1.73  0.48 2.24  0.54
NM_007670 Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Cdkn2b 1.51  0.34 1.85  0.50 1.76  0.63
NM_173378 Transformation-related protein 53 binding protein 2 Trp53bp2 1.24  0.31 1.19  0.48 1.85  0.54
NM_010786 Transformed mouse 3T3 cell double minute 2 Mdm2 –1.03  0.31 1.68  0.48 2.38  0.54
NM_008575 Transformed mouse 3T3 cell double minute 4 Mdm4 1.38  0.36 1.74  0.50 2.63  0.57
NM_001003918 Ubiquitin specific peptidase 7 Usp7 1.31  0.33 1.88  0.48 1.48  0.55
NM_175089 NIMA (never in mitosis gene a)-related expressed kinase 1 Nek1 1.08  0.66 1.58  0.67 1.65  0.77
NM_021606 NIMA (never in mitosis gene a)-related expressed kinase 6 Nek6 1.31  0.31 2.10  0.48 2.39  0.54
NM_010937 Neuroblastoma ras oncogene Nras 1.08  0.31 1.97  0.48 2.88  0.54
NM_009174 Seven in absentia 2 Siah2 1.60  0.32 1.31  0.49 2.40  0.54
NM_022021 CDK5 and Abl enzyme substrate 1 Cables1 –1.42  0.36 –1.90  0.51 –1.84  0.56
NM_016746 Cyclin C Ccnc –1.87  0.32 –2.44  0.49 –5.40  0.55
NM_007631 Cyclin D1 Ccnd1 –2.44  0.31 –1.34  0.48 –1.99  0.55
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Table 1 Continued
GenBank Gene title Symbol 8 hrs 15 hrs 24 hrs
NM_009829 Cyclin D2 Ccnd2 –1.79  0.31 –1.38  0.48 –2.44  0.54
NM_009830 Cyclin E2 Ccne2 –2.22  0.34 –1.92  0.49 –2.23  0.55
NM_007634 Cyclin F Ccnf –1.21  0.50 –1.96  0.62 –2.13  0.65
NM_023243 Cyclin H Ccnh –2.36  0.31 –1.82  0.48 –2.24  0.54
NM_172839 Cyclin J Ccnj –1.35  0.32 –1.72  0.48 –2.18  0.54
NM_001045530 Cyclin J-like Ccnjl –1.75  0.32 –1.78  0.48 –3.95  0.55
NM_001080818 CDC14 cell division cycle 14 homologue A (S. cerevisiae) Cdc14a –1.52  0.44 –1.30  0.55 –5.73  0.64
NM_178347 CDC23 (cell division cycle 23, yeast, homologue) Cdc23 –1.41  0.31 –2.13  0.48 –2.42  0.54
NM_007658 Cell division cycle 25 homologue A (S. pombe) Cdc25a –1.44  0.32 –1.75  0.49 –3.21  0.54
NM_139291 Cell division cycle 26 Cdc26 –1.43  0.31 –1.81  0.48 –2.36  0.54
NM_025950 Cell division cycle 37 homologue (S. cerevisiae)-like 1 Cdc37l1 –1.27  0.32 –1.88  0.48 –1.93  0.55
NM_013538 Cell division cycle associated 3 Cdca3 –1.00  0.32 –1.45  0.49 –8.16  0.54
NM_016756 Cyclin-dependent kinase 2 Cdk2 –1.29  0.32 –1.79  0.49 –2.15  0.55
NM_009873 Cyclin-dependent kinase 6 Cdk6 –1.19  0.32 –1.91  0.48 –3.65  0.54
NM_009874
Cyclin-dependent kinase 7 (homologue of Xenopus 
MO15 cdk-activating kinase)
Cdk7 –2.10  0.35 –2.56  0.52 –9.89  0.55
NM_172717 Checkpoint with forkhead and ring finger domains Chfr –1.12  0.31 –2.17  0.48 –2.03  0.54
NM_010093 E2F transcription factor 3 E2f3 –2.13  0.31 –2.72  0.48 –2.32  0.54
NM_146066 G1 to S phase transition 1 Gspt1 –1.43  0.31 –2.19  0.48 –2.80  0.54
NM_026933 TP53-regulated inhibitor of apoptosis 1 Triap1 –1.38  0.31 –1.93  0.48 –1.55  0.54
Endoplasmic reticulum (ER) stress
 6, P  3.23
 5, P  0.44
 6, P  2.23
 5, P  0.42
 6, P  1.93
 5, P  0.42
NM_009883 CCAAT/enhancer binding protein (C/EBP), 	 Cebpb 2.47  0.65 4.10  0.49 3.53  0.55
NM_007837 DNA-damage inducible transcript 3 Ddit3 2.12  0.66 5.75  0.48 7.10  0.79
NM_021451 Phorbol-12-myristate-13-acetate-induced protein 1 Pmaip1/Noxa 2.66  0.33 3.29  0.49 5.63  1.15
NM_133234 Bcl2 binding component 3 Bbc3/Puma 1.18  0.31 3.00  0.49 5.83  1.25
NM_024207 Der1-like domain family, member 1 Derl1 1.07  0.31 1.57  0.48 2.12  0.54
NM_010121 eukaryotic translation initiation factor 2 kinase 3 Eif2ak3 1.44  0.31 1.87  0.48 2.18  0.54
NM_015774 ERO1-like (S. cerevisiae) Ero1l 1.06  0.32 2.09  0.48 2.63  0.54
NM_022331
Homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1
Herpud1
1.40  0.36 2.28  0.48 3.11  0.54
NM_011644
Transient receptor potential cation channel, subfamily C,
member 2
Trpc2 1.81  0.50 1.93  0.57 2.02  0.62
NM_029572 Thioredoxin domain containing 4 (endoplasmic reticulum) Txndc4 1.15  0.31 1.64  0.48 1.83  0.54
NM_138677 ER degradation enhancer, mannosidase -like 1 Edem1 –1.66  0.32 –1.91  0.48 –1.55  0.54
Response to oxidative stress
 16, P  3.22
 N/A
 16, P  1.32
 N/A
 16, P  8.35
 N/A
NM_013603 Metallothionein 3 Mt3 1.04  0.31 2.14  0.48 2.07  0.54
NM_008706 NAD(P)H dehydrogenase, quinone 1 Nqo1 1.33  0.38 2.31  0.66 3.03  0.57
NM_011034 Peroxiredoxin 1 Prdx1 1.28  0.31 2.05  0.48 2.08  0.55
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Table 1 Continued
GenBank Gene title Symbol 8 hrs 15 hrs 24 hrs
NM_007453 Peroxiredoxin 6 Prdx6 1.07  0.31 2.21  0.48 2.48  0.54
NM_019913 Thioredoxin 2 Txn2 1.11  0.31 1.59  0.48 1.87  0.54
NM_029572 Thioredoxin domain containing 4 (endoplasmic reticulum) Txndc4 1.15  0.31 1.64  0.48 1.83  0.54
NM_015762 Thioredoxin reductase 1 Txnrd1 1.61  0.37 2.51  0.56 3.40  0.56
NM_011198 Prostaglandin-endoperoxide synthase 2 Ptgs2 8.53  0.77 25.00  7.40 37.22  1.70
NM_010442 Heme oxygenase (decycling) 1 Hmox1 18.03 8.04 67.24 1.05 86.75  8.99
NM_029688 Sulfiredoxin 1 homologue (S. cerevisiae) Srxn1 4.72  1.63 11.32  0.48 12.87  2.58
NM_011847 DnaJ (Hsp40) homologue, subfamily B, member 6 Dnajb6 –1.16  0.53 1.86  0.60 1.86  0.64
NM_007869 DnaJ (Hsp40) homologue, subfamily C, member 1 Dnajc1 2.14  0.41 3.93  1.26 3.11  0.59
NM_010481 Heat shock protein 9 Hspa9 1.18  0.31 1.57  0.48 2.31  0.54
NM_030704 Heat shock protein 8 Hspb8 1.73  0.55 4.65  0.52 4.86  0.58
NM_013863 BCL2-associated athanogene 3 Bag3 2.04  0.36 2.77  0.51 2.07  0.57
NM_009825 Serine (or cysteine) peptidase inhibitor, clade H, member 1 Serpinh1 1.35  0.34 4.77  0.75 4.02  0.54
NM_019794 DnaJ (Hsp40) homologue, subfamily A, member 2 Dnaja2 –1.33  0.31 –1.82  0.48 –2.26  0.54
NM_018808 DnaJ (Hsp40) homologue, subfamily B, member 1 Dnajb1 –1.80  0.31 –2.04  0.48 –1.89  0.54
NM_008300 Heat shock protein 4 Hspa4 –1.00  0.31 –2.27  0.48 –1.89  0.54
NM_178385 Tubulin-specific chaperone c Tbcc –1.34  0.34 –2.55  0.49 –3.31  0.55
NM_001033149 Tetratricopeptide repeat domain 9 Ttc9 –1.41  0.31 –2.14  0.48 –1.75  0.54
Ubiquitin mediated proteolysis
 24, P  2.35
 17, P  8.93
 21, P  1.84
 36, P  4.47
 21, P  1.814
 36, P  4.17
NM_028288 Cullin 4B Cul4b 1.23  0.32 1.67  0.48 2.16  0.54
NM_176848 F-box protein 2 Fbxo2 1.32  0.33 2.80  0.48 3.83  0.54
NM_172721 F-box and WD-40 domain protein 8 Fbxw8 3.08  0.60 5.42  1.58 4.86  0.68
NM_026101 Hect domain and RLD 4 Herc4 1.16  0.46 1.37  0.71 1.95  0.60
NM_026557 Ring finger and CHY zinc finger domain containing 1 Rchy1 1.23  0.31 1.76  0.48 2.22  0.54
NM_029438 SMAD specific E3 ubiquitin protein ligase 1 Smurf1 1.22  0.38 3.13  0.61 4.18  0.56
NM_019719 STIP1 homology and U-Box containing protein 1 Stub1 –1.21  0.33 1.38  0.49 1.48  0.55
NM_011965 Proteasome (prosome, macropain) subunit,  type 1 Psma1 1.14  0.37 1.81  0.51 1.64  0.56
NM_011184 Proteasome subunit C8 (Psma3) Psma3 1.35  0.61 2.13  0.52 2.30  0.61
NM_013585
Proteasome (prosome, macropain) subunit, 
	 type 9 (large multifunctional peptidase 2)
Psmb9 1.52  0.39 2.07  0.52 1.99  0.57
NM_026785 Ubiquitin-conjugating enzyme E2C Ube2c 1.37  0.31 1.96  0.48 –2.16  0.54
NM_173010 Ubiquitin protein ligase E3A Ube3a 1.38  0.32 1.79  0.48 2.20  0.54
NM_145400 Ubiquitination factor E4A (UFD2 homologue, S. cerevisiae) Ube4a 1.69  0.67 1.99  0.51 2.17  0.56
NM_177327 WW domain containing E3 ubiquitin protein ligase 1 Wwp1 1.20  0.31 1.67  0.48 1.76  0.54
NM_172712 Ubiquitin-like modifier activating enzyme 6 Uba6 –1.82  0.33 –2.17  0.52 –1.96  0.55
NM_145420
Ubiquitin-conjugating enzyme E2D 1 
(UBC4/5 homologue, yeast)
Ube2d1 –1.37  0.31 –2.15  0.48 –1.98  0.54
Continued
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genes with known pathway associations in either the identified
DAVID gene-ontology categories or the comprehensive identified-
gene lists that were not found by the analyses. The overall
approach to derive inferences from global gene profiles has been
previously documented in several microarray articles [30–32].
In this study, we focus on the over-represented biological
processes (with EASE-determined P  0.05) induced in nitric
oxide mediated neuronal injury (Table 1) and some of which are
listed later. For the purpose of clear distinction during reference to
proteins and genes, gene symbols in the text are in italics.
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GenBank Gene title Symbol 8 hrs 15 hrs 24 hrs
NM_025356
Ubiquitin-conjugating enzyme E2D 3 
(UBC4/5 homologue, yeast)
Ube2d3 –1.23  0.31 –2.38  0.49 –1.80  0.54
NM_025985
Ubiquitin-conjugating enzyme E2G 1 
(UBC7 homologue, C. elegans)
Ube2g1 –1.46  0.31 –2.15  0.48 –1.91  0.54
NM_016786
Ubiquitin-conjugating enzyme E2K 
(UBC1 homologue, yeast)
Ube2k –1.30  0.33 –3.11  0.49 –1.51  0.55
NM_027315 Ubiquitin-conjugating enzyme E2Q (putative) 1 Ube2q1 –1.79  0.31 –2.76  0.48 –3.48  0.54
NM_133907 Ubiquitin protein ligase E3C Ube3c –1.47  0.31 –1.90  0.48 –1.73  0.54
NM_080562 U box domain containing 5 Ubox5 –2.08  0.33 –2.57  0.51 –2.82  0.55
Glutathione metabolism
 5, P  0.06
 N/A
 12, P  1.14
 N/A
 5, P  0.04
 N/A
NM_008160 Glutathione peroxidase 1 Gpx1 1.29  0.32 1.89  0.48 1.69  0.54
NM_010344 Glutathione reductase Gsr 1.29  0.31 2.18  0.48 3.49  0.75
NM_008180 Glutathione synthetase Gss 1.25  0.43 3.19  0.48 4.54  0.54
NM_008182 Glutathione S-transferase, 1 Gsta1 2.69  1.32 10.45  0.58 32.10  7.71
NM_008182 Glutathione S-transferase, 2 (Yc2) Gsta2 2.66  0.71 8.68  0.79 26.73  9.86
NM_010357 Glutathione S-transferase, 4 Gsta4 1.46  0.34 5.78  0.48 11.58  1.15
NM_010358 Glutathione S-transferase, mu 1 Gstm1 1.21  0.31 2.86  0.48 3.27  0.54
XM_904332
Glutathione reductase, mitochondrial precursor 
(GR) (GRase)
LOC630729 1.47  0.36 2.15  0.48 3.39  0.54
NM_019946 Microsomal glutathione S-transferase 1 Mgst1 1.09  0.31 2.65  0.48 2.47  0.54
Nitric oxide metabolism
63, P  1.36
45, P  0.22
 21, P  0.31
 44, P  0.23
19, P  0.42
 44, P  0.22
NM_007494 Argininosuccinate synthetase 1 Ass1 2.39  0.42 4.16  0.60 8.57  1.56
NM_013463 Galactosidase,  Gla 1.73  0.32 3.33  0.48 2.76  0.54
NM_145953 Cystathionase (cystathionine gamma-lyase) Cth 1.44  0.51 2.66  0.49 3.25  0.54
NM_008131 Glutamate-ammonia ligase (glutamine synthetase) Glul –1.08  0.31 1.61  0.48 –1.41  0.54
NM_013614 Ornithine decarboxylase, structural 1 Odc1 1.35  0.31 1.87  0.48 2.18  0.54
NM_008987 Pentraxin-related gene Ptx3 1.79  0.32 2.68  0.48 1.63  0.54
NM_013646 RAR-related orphan receptor  Rora 1.78  0.34 2.74  0.66 2.94  0.55
NM_023141 Torsin family 3, member A Tor3a 1.71  0.38 1.64  0.52 1.81  0.57
Numerical value after  /  indicates gene count up or down-regulated respectively at designated time-point, and P corresponds to modified Fisher’s
exact P value, EASE Score; the smaller the more enriched; usually P value is equal or smaller than 0.05 to be considered strongly enriched in the
annotation categories. Default set for EASE Score Threshold (maximum probability is 0.1). All fold-change expressions are subjected to one-way ANOVA
analysis and significant at P  0.05. Data are expressed as fold-change  S.E.
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Cell death
A significant number of cell death cascade-related genes demon-
strated increase in gene expression which were altered from as early
as 8 hrs (Table 1). Genes such as Dapk2, Bcl2l11 and Tnfrsf12a
demonstrated significant up-regulation at early 8 hrs nitric oxide
post-treatment, with maintenance of consistently increasing expres-
sion throughout the time-course. Gene candidates potentially up-
regulated from 15 hrs composed of Angptl4, Dap and Ripk1.
Cell survival
Cellular survival-promoting protein-encoding genes, particularly
growth factors, for example Bdnf, Igf1 and Tgfb2 and their receptors,
for example Egfr and Fgfr2 showed elevated gene expression at early
8 hrs. To complicate matters, genes critical in neuronal regeneration
after injury, such as Nrn1 and Nr4a2 also demonstrated an early
increase in gene expression. Simultaneous transcriptional elevation
also occurred to the tumour necrosis receptors associated factors
(Trafs), for example Traf3 and Traf5, pro-survival signalling mole-
cules negatively regulated downstream of Pawr. Transcription fac-
tors such as FBJ osteosarcoma oncogene (Fos and Fosb) and Jun
oncogene (Jun and Junb) which target pro-survival genes demon-
strated substantial transcriptional up-regulation at 8 hrs.
Mitotic cell cycle regulation
As demonstrated in Table 1, several genes involved in cell cycle
progression such as the cyclins (Ccna2, Ccnb1, Ccng1 and Ccnl1)
cell division cycle homologues (Cdc20, Cdc27 and Cdc2l5) and
cyclin-dependent kinase (Cdk7) were mostly highly up-regulated
at 15 hrs time-point. Simultaneously, most of the genes encoding
for other subtypes of cyclins and cyclin-dependent kinases (Cdks)
demonstrated significant persistent decrease in gene expression.
On the contrary, genes that encode for proteins involved in the
impediment of cell cycle progression, particularly from those of
the p53-dependent pathway, such as Trp53bp2, Gadd45a,
Gadd45b, Gadd45g, Cdkn1a, Cdkn2b and p53 endogenous
inhibitor, Mdm2 gene expression showed an up-regulation to
counteract cell cycle re-activation.
Endoplasmic reticulum stress
A significant transcriptional elevation of severe endoplasmic retic-
ulum (ER) stress-induced pro-apoptotic genes was observed in
nitric oxide mediated neuronal injury. These genes composed of
Ddit3, Cebpb and Pmaip1, which were highly up-regulated at 
8 hrs, and Bbc3, Derl1, Herpud1, Ero1l and Trpc2 at 15 hrs 
NOC-18 post-treatment as shown in Table 1.
Calcium homeostasis and binding
With the activation of the calcium-dependent calpains (Fig. 2B), it
was worthy to examine the regulatory trend of genes encoding for
proteins involving in calcium ion homeostasis. Genes encoding 
for proteins involved in calcium homeostasis and binding were
significantly up-regulated in nitric oxide mediated neuronal injury
at 8 hrs (Table 1). Examples of these genes include S100a1,
S100a4, Anxa3, AnxA5, Fkbp9 and Fkbp10.
Response to oxidative stress
In response to the cellular oxidative stress, antioxidant pathways
were triggered perhaps in an attempt to rescue to the neuron from
oxidative stress-related cell death. These genes consisted of
Ptgs2, Hmox1 and Srxn1, which were up-regulated at 8 hrs and
Mt3, Nqo1 and peroxiredoxins (Prdx1 and Prdx6) at 15 hrs.
Furthermore, a handful of genes that encodes for chaperone 
proteins to alleviate cellular stress in response to aberrant protein
formation were induced at 15 hrs in nitric oxide mediated neuronal
injury (Table 1). These genes composed of Dnajb6 and Dnajc1
(Hsp40), Hspa9 (Hsp70), Hspb8 (Hsp22) and Serpinh1 (Hsp47).
Ubiquitin-mediated proteolysis
As nitric oxide is able to trigger protein modifications, it is impor-
tant to ensure functionality of the ubiquitin–proteasome system
(UPS) to perform the necessary protein clearance to reduce aber-
rant protein buildup. A significant proportion of UPS-related genes
underwent significant and vast transcriptional regulation in nitric
oxide mediated neuronal injury. Most ubiquitin-conjugating
enzymes involved in ligation of ubiquitin protein/polypeptide des-
tined for degradation (e.g. Ube2c, Ube2d1, Ube2g1 and especially
Ube2q) were significantly down-regulated, whereas others (e.g.
ubiquitin ligases: Siah2, Smurf1 and Ube3a) demonstrated 
transcriptional up-regulation. However, genes encoding for pro-
teasome subunits Psma1, Psma3 and Psmb9 still demonstrated
elevated gene expression. Time-point-specific statistical analyses
using modified Fisher’s exact P value demonstrated a statistical
significant suppression of gene expression among UPS members,
an indication of UPS dysfunction.
Glutathione metabolism
Consistent with reports that glutathione (GSH) showed neuropro-
tective against nitrergic neuronal injury through sequestration of
nitric oxide by formation of nitrosoglutathione (GSNO), remark-
ably increases in transcriptional expression of GSH metabolism
related proteins (e.g. Gpx1, Gsr, Gsta1, Gsta2 and Gsta4) were
observed and documented in nitric oxide global gene profile.
Nitric oxide metabolism
Genes encoding for proteins participating in nitric oxide involved
multistep metabolic pathways such as urea cycle (Ass1, Gla, Ptx3
and Tor3a) were highly up-regulated from the early 8 hrs time-point.
Validation of microarray analysis
Microarray data were validated via Western blotting and real-time
PCR and indicated a high degree of reliability and specificity.
© 2011 The Authors
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Immunoblot analyses (Table 2) and real-time PCR data (Table 3)
both confirmed the differential expression profile induced by 
0.5 mM NOC-18 treatment.
Discussion
The global gene profiling in this study reflects the simultaneous
transcriptional activation and/or inhibition of multiple signalling
cascades in nitric oxide mediated neuronal injury wherein 3672
probe sets demonstrated at least 1.5-fold change in a minimum
of one of three time-points (8, 15 and 24 hrs). These data provides
an overview of the multi-interactive functions of nitric oxide with
induction and inhibition various signalling pathways during the
course of its induction of neuronal death. We found recruitment of
several biological processes, including apoptotic cell death, 
survival, cell cycle, ER stress, antioxidative stress response,
energy production, ubiquitin-mediated proteolysis, GSH and nitric
oxide metabolism. As demonstrated in our study, the final
neuronal decision to undergo cell death or survival is determined
by the net coordinated effect between the pro- and antiapoptotic
proteins. The evidence from our study further confirms the role
that nitric oxide plays in the exacerbation of neuronal injury, thus
highlighting the importance of its contribution to the pathogenesis
of several neurodegenerative diseases where severe cellular
oxidative stress is frequently experienced [19]. An understanding
of the multiple mechanisms of nitric oxide mediated neuronal
© 2011 The Authors
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Table 2 Immunoblotting validation of microarray data performed on 24 hrs 0.5 mM NOC-18-treated murine primary cortical neuron culture
Gene title Gene symbol
Gene expression
(microarray)
Protein expression (Western blot)
Control Treated
Annexin A3 Anxa3 10.3  1.3 37 kD
Cyclin D1 Ccnd1 –2.0  0.5 36 kD
Cell division cycle 25 homologue A (S. pombe) Cdc25a –3.2  0.5 65 kD
Heat shock 70 kD protein 8 
Heat shock 70 kD protein 9 
Heat shock 70 kD protein 14
Hspa8 Hspa9
Hspa14
9.2  0.8 
2.3  0.5 
2.1  0.5
70 kD
Serine (or cysteine) peptidase inhibitor, 
clade H, member 1 (47 kD heat shock protein)
Serpinh1 (HSP47) 4.0  0.5 47 kD
	-Tubulin 
(internal control)
54 kD
Gene regulation expressed as fold-change  S.E. Each immunoblot is representative of three independent experiments. Densitometric analysis chart
(above) further illustrated the correlation between protein expression and transcriptional expression.
Table 3 Real-time PCR-based validation of microarray data on 24 hrs 0.5 mM NOC-18-treated murine primary cortical neurons
GenBank Gene title Symbol Microarray (24 hrs) Real-time PCR (24 hrs)
NM_020581 Angiopoietin-like 4 Angptl4 2.63  0.57 4.56  0.69
NM_007837 DNA-damage inducible transcript 3 Ddit3 7.10  0.79 5.05  0.70
NM_011817 Growth arrest and DNA-damage-inducible 45 Gadd45g 8.80  0.54 14.64  0.75
NM_010442 Heme oxygenase (decycling) 1 Hmox1 86.75  8.99 61.54  1.67
NM_030704 Heat shock protein 8 Hspb8 4.86  0.58 4.73  0.98
NM_011198 Prostaglandin-endoperoxide synthase 2 Ptgs2 37.22  1.70 36.84  0.87
Data are expressed as fold-change  S.E. Each real-time PCR probe data is representative of three independent replicates.
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injury is advantageous for the better identification of potential bio-
logical targets in the intervention of neurodegenerative disease
progression. Indeed, we have been able to provide major insights
towards such a goal, including the revelation of the major cellular
mechanisms contributing to the nitrergic neuronal injury and their
temporal patterns of recruitment.
Time-course of gene profiling in relationship 
to cellular signalling
Based on temporal recruitment of over-represented biological
processes, we are able to postulate an overview of nitric oxide
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 Time-course analysis of nitric oxide global gene profile demonstrates the sequential activation and/or inhibition of the respective cellular signalling
cascades upon nitric oxide entry into the neuron in nitric oxide mediated neuronal injury.
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induction of neuronal death formulated upon the temporal pattern
of transcriptomic changes (Fig. 5).
Early- and medium-term events (8–15 hrs processes)
(1) Nitric oxide, a membrane-permeable gas diffuses through
the cellular membrane.
(2) (a) Because of its excess presence, the nitric oxide metabolic
pathways such as the urea cycle are activated in an attempt
to remove the exogenous nitric oxide. Evident from the 
transcriptomic profile of nitric oxide mediated neuronal
injury, the Ass1 gene which encodes for arginosuccinate
synthase 1 in the urea cycle for removal of excess nitric
oxide, was especially up-regulated at the early 8 hrs time-
point. (b) Simultaneously, because of its thermodynamic
instability, nitric oxide interacts with other cellular gaseous
molecules or ROS to form highly reactive free radicals and
nitrergic free radical species (•NO2, •NO and ONOO).
(3) These radicals and ions induced genotoxic damage and pro-
tein modifications, leading to increase oxidative stress. (a)
Further, oxidative stress-mediated homeostatic ionic imbal-
ance leads to increase Ca2 cytosolic influx from intra- and
extracellular compartments. In fact, perturbed Ca2 ion
homeostasis is obvious from nitric oxide transcriptomic pro-
file with increase in gene expression of Ca2-dependent pro-
teins including pro-apoptotic serine/threonine kinase Dapk2
(Table 1: Cell death), annexins and S100 and FK506 calcium
binding proteins. This finding implies an occurrence of exci-
totoxic event with an increase in intracellular Ca2 level,
leading to activation of Ca2-activated proteins such as cal-
cineurin and calpains (Fig. 2), which mediated cleavage of -
fodrin to 145/150 kD fragments.
(4) Electrophilic stress together with abundant presence of mis-
assembled proteins in ER lumen, converged to ER stress.
Also known as ER-associated degradation (ERAD), this sys-
tem governs ubiquitin-dependent degradation of misfolded
ER proteins mediated by ER proteins. Derl1, Herpud1 and
Edem1 are ER stress-inducible proteins involved in ERAD
which demonstrated significant elevated gene expression at
15 hrs post-treatment in nitric oxide mediated neuronal
injury. Nitric oxide mediated ER stress is also prominent
from the substantial increase in gene expression of ER
stress-responsive pro-apoptotic genes particularly DNA-
damage inducible transcript 3 (Ddit3), CCAAT/enhancer
binding protein (Cebpb), phorbol-12-myristate-13-acetate-
induced protein 1 (Pmaip1), Bcl2-binding component 3
(Bbc3; Table 1: ER stress). (C/EBP) 	, which was highly up-
regulated at the early 8 hrs NOC-18 post-treatment.
Dimerization of Ddit3 protein with its partner, Cebpb protein,
forms a repressor complex, which inhibits transcription of
survival-promoting genes. Bbc3, also known as p53-upregu-
lated modulator of apoptosis (Puma), together with Pmaip1
(Noxa), are p53-mediated ER stress responsive genes as
they encode BH3-only proteins, pro-apoptotic members of
the Bcl-2 family required to initiate apoptosis through dis-
placement of Bcl2 and Bcl-xL inhibitory interactions with the
pro-apoptotic proteins Bax and/or Bak facilitating mitochon-
drial outer membrane permeabilization and cytochrome c
release [33].
(5) Cellular stress leads to activation of Hsps and chaperones
that work to alleviate the stress and restore homeostasis. It
has been reported that nitric oxide can exert antiapoptotic
effect through induction of cytoprotective gene expression
[34]. As a result, several Hsps and chaperones (e.g. Hspa9,
Hspb8, Bag3 and Serpinh1), peroxiredoxins (Prdx1 and
Prdx6) and metallochaperone, Mt3, demonstrated significant
increases in gene expression in nitric oxide mediated neu-
ronal injury with Ptgs2, Hmox1 and Srxn1 being especially
highly up-regulated (Table 1: Response to oxidative stress).
(6) Concomitantly, the pro-survival pathways such as growth
factor signalling pathways are activated to promote cell
preservation. Several of these genes play multifunctional
roles in the antiapoptotic process. Birc6 (also known as
Bruce), which demonstrated elevated gene expression from
15 hrs (Table 1: Cell survival), is a trans-Golgi peripheral
membrane protein that functions as an effective inhibitor of
apoptosis (IAP) by inhibition of caspase activity through its
Bir domain [35]. It also contains an intrinsic E2/E3 ubiquitin
ligase activity that targets Smac for degradation [35].
Deletion of the C-terminal end of Birc6 including the Bir
domain resulted in increased p53 expression and nuclear
localization with concomitant activation of mitochondrial-
dependent apoptosis [36]. The tumour necrosis factor recep-
tor associated factors (Trafs) were significantly up-regulated
at 8 hrs. Traf5 have been reported to be involved in Tnf-
induced nuclear factor B (NF-B) activation, resulting in
increased transcriptional activity of pro-survival genes and
subsequent protection from cell death [37].
• Late events (15–24 hrs processes)
(7) As oxidative stress is further aggravated at the later stages,
more Hsps and chaperones are activated. GSH metabolic
pathway, the strong mammalian antioxidant signalling cas-
cade, also comes into play. Correspond to genes encoding
Hsps and molecular chaperones, members of the GSH path-
way including glutathione peroxidase 1 (Gpx1), glutathione
reductase (Gsr) and glutathione S-transferase (Gst) also
demonstrated extensive up-regulation in nitric oxide medi-
ated neuronal injury from as early as 8 hrs (Table 1: GSH
metabolism) furthering validating the early occurrence of
oxidative stress imposed by high levels of ROS. Gst genes,
especially those encoding the  class (Gsta1, Gsta2 and
Gsta4), were highly up-regulated up to multiple of 10-folds
gene expression. Gsts are involved in the detoxification of a
wide variety of substrates through conjugation of reduced
GSH to the electrophilic centre of the compound via a
sulfhydryl group. Moreover, the glutathione synthase (Gss)
involved in GSH biosynthesis also demonstrated elevated
gene expression at 15 hrs, a further indication of intense cel-
lular oxidative stress.
(8) As the extent of DNA damages becomes increasingly severe,
coupling with strong mitogenic signal transduction to pro-
mote cell cycle re-activation, the p53 signalling pathway is
© 2011 The Authors
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brought into the picture to inhibit cell cycle re-entry and
enhance the cell death progression. In vitro [38] and in vivo
[39] studies have shown that terminally differentiated neu-
rons destined for cell death are able to replicate DNA. A study
by Kruman et al. [40] further confirmed that cell cycle re-acti-
vation is a vital component of DNA damage response of post-
mitotic neurons that can result in apoptosis. Several cell
cycle phase progression genes such as cyclins (Ccna2,
Ccnl1 and Ccnt2) cell division cycle homologues (Cdc20,
Cdc27, Cdc2l5 and Cdc73), FBJ osteosarcoma oncogene
(Fos and Fosb) and Jun oncogene (Jun and Junb) showed
significant up-regulation in nitric oxide mediated neuronal
injury. However, attempt to revive the cell cycle machinery
was counteracted by the activation of the p53 signalling
pathway, as evident by gene up-regulation of its binding part-
ner (Trp53bp2), growth arrest and DNA damage-inducible
(Gadd45) family, cyclin B1 (Ccnb1) and G1 (Ccng1) and cell-
dependent kinase inhibitors (Cdkn1a and Cdkn2b), which
were related to cell cycle progression and/or DNA damage
response. Cdkn1a, commonly known as p21, is involved in
the inhibition of critical Cdks activity by hindering their phos-
phorylation of downstream cell cycle substrate, thus leading
to a blockade of cell cycle progression. Gadd45a, Gadd45b
and Gadd45g interact with both Cdk1 and cyclin B1, to
induce inhibition of the kinase activity of the Cdk1/cyclin B1
complex upon genotoxic stress resulting in G2/M cell cycle
arrest [41].
(9) Oxidative stress results in impairment of the mammalian
protein clearance machinery. With the mounting accumula-
tion of aberrant proteins in the ER lumen, ER activates its
ERAD response to increase protein turnover via the UPS
route. As such, it is crucial that the cellular inherent protein
clearance pathway is functioning optimally to handle the high
rate of protein degradation. We have previously reported the
presence of UPS dysfunction in nitric oxide mediated neu-
ronal injury [42]. As shown in Table 1, ubiquitin-mediated
proteolysis was impaired with the significant down-regulation
of majority of the ubiquitin-conjugating enzymes which are
crucial in the preparation of proteins for targeted degradation
by the proteasomes.
(10) With the increasing homeostatic imbalance inflicted by the
perturbation of various biological processes that is beyond
restoration, the neuron triggers the cell death machinery,
sending itself to demise. When the relative effect of the 
pro-death molecules overwhelms that of the pro-survival
components, the cell death machinery is triggered via the
activation of multiple cell death signalling cascades including
the mitochondrial-dependent cytochrome c mediated sig-
nalling pathway [43], p53-mediated apoptotic signalling
pathway (discussed in early/medium-term processes) [44],
and the Fas pathway.
Conclusion
Our study has for the first time addressed concurrently the multi-
ple signalling mechanisms regulated/affected by nitric oxide in its
course of mediation of neuronal death. This global gene profiling
represents a novel database in term of the temporal patterns of
recruitment of signalling cascade to nitrergic neuronal injury. This
global gene profile of nitric oxide mediated neuronal injury pro-
vides the very initial phase of screening of potential protein candi-
dates whose gene expression can be inhibited or stimulated to
form the basis for therapeutic interventions in several neurode-
generative disorders.
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